Lonza, a major CDMO, is to invest $518 million in a new, massive fill-finish manufacturing facility in Stein, Switzerland. According to the firm, the facility will use sustainable construction methods to lower carbon emissions when it is finished in 2026.
According to Lonza, the project would symbolise the achievement of the company’s ambition to provide comprehensive end-to-end CDMO services. The building will be situated on the same campus as the business’s current Stein facility for clinical medicinal products.
Lonza’s CEO, Pierre-Alain Ruffieux, said in a statement that “this strategic investment reinforces their position as a leading CDMO with an unrivalled variety of services across scales and technologies.”
Lonza has been expanding recently, similar to many CDMOs. The company’s laboratory expansion plan at its API production facility in Nansha, China, was finished in March. Lonza’s Guangzhou, China, factory, which had just opened for business earlier in the year, added a fill-finish line in August. The business also operates a factory in Suzhou, China, where it sells medication capsules and antimicrobial treatments. Lonza said in May of last year that it would spend $935 million to construct mammalian facilities at locations in Visp, Switzerland, and Portsmouth, New Hampshire.